Repligen Corporation (NASDAQ:RGEN) Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc lessened its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 23.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 804,511 shares of the biotechnology company's stock after selling 247,428 shares during the period. Impax Asset Management Group plc owned approximately 1.43% of Repligen worth $101,491,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Oppenheimer & Co. Inc. purchased a new stake in Repligen during the 4th quarter worth approximately $216,000. KBC Group NV grew its position in Repligen by 14.9% during the 1st quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock worth $324,000 after purchasing an additional 329 shares during the last quarter. LPL Financial LLC grew its position in Repligen by 47.6% during the 4th quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock worth $4,873,000 after purchasing an additional 10,395 shares during the last quarter. Signaturefd LLC grew its position in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 124 shares during the last quarter. Finally, US Bancorp DE grew its position in Repligen by 1.9% during the 4th quarter. US Bancorp DE now owns 10,222 shares of the biotechnology company's stock worth $1,471,000 after purchasing an additional 190 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Stock Performance

Shares of RGEN traded down $3.04 during trading hours on Monday, hitting $124.43. The stock had a trading volume of 424,625 shares, compared to its average volume of 728,222. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. The firm has a 50-day moving average price of $126.32 and a 200 day moving average price of $139.73. Repligen Corporation has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The firm has a market capitalization of $6.99 billion, a price-to-earnings ratio of -276.51, a PEG ratio of 3.65 and a beta of 1.11.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The firm had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same period in the previous year, the business posted $0.28 EPS. The business's revenue was up 10.4% compared to the same quarter last year. As a group, research analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Analyst Ratings Changes

Several analysts have weighed in on RGEN shares. Royal Bank Of Canada dropped their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective for the company. Canaccord Genuity Group decreased their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Barclays started coverage on shares of Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price objective for the company. Finally, Wall Street Zen cut shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Repligen currently has an average rating of "Moderate Buy" and an average price target of $172.83.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.